1.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KU36-44, D0810C00008, NCT00494234
|
|
2.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KU36-58, D0810C00009, NCT00494442
|
|
3.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00012, NCT00628251
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00020, NCT00679783
|
|
5.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00019, NCT00753545
|
|
6.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D9010C00008, AGICC 09CRC01, NCT00912743
|
|
7.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00039, NCT01063517
|
|
8.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00042, NCT01078662
|
|
9.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00041, NCT01081951
|
|
10.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: I187, CAN-NCIC-IND187, IND187, CDR0000565189, NCT00535353
|
|
11.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00005, KU36-29, NCT00515866
|
|
12.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00002, KU36-92, NCT00516373
|
|
13.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KU36-93, D0810C00006, NCT00516438
|
|
14.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00004, KU36-96, NCT00516724
|
|
15.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KU36-73, D0810C00003, NCT00516802
|
|
16.
|
Phase: Phase I Type: Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00001, NCT00572364
|
|
17.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00010, KU36-37, NCT00633269
|
|
18.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-08-C-0128, 08-C-0128, P07286, NCT00678132
|
|
19.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00011, NCT00707707
|
|
20.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00022, NCT00710268
|
|
21.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810C00021, NCT00782574
|
|
22.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D0810L00001, Eudract No. 2008-007680-17, NCT00819221
|